Protalix BioTherapeutics, Inc. (PLX) earnings date, results and what the price requires
NYSE · SEC CIK 0001006281 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 12, 2026 | $19.9M | $3.8M | $0.05 | Filing |
| Mar 31, 2026 | May 13, 2026 | $33.8M | $18.3M | $0.22 | Filing |
| Dec 31, 2025 | Mar 18, 2026 | $9.1M | $-5.5M | $-0.06 | Filing |
| Sep 30, 2025 | Nov 13, 2025 | $17.9M | $2.4M | $0.03 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | $15.7M | $164,000 | $0.00 | Filing |
| Mar 31, 2025 | May 9, 2025 | $10.1M | $-3.6M | $-0.05 | Filing |
| Dec 31, 2024 | Mar 17, 2025 | $18.2M | $6.5M | $0.10 | Filing |
| Sep 30, 2024 | Nov 14, 2024 | $18.0M | $3.2M | $0.03 | Filing |
What would Protalix BioTherapeutics, Inc. have to report for its valuation to change?
At $2.62, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -1.4% a year, to $0.22. On that path the next quarter needs diluted EPS near $0.03, against $0.03 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -1.4% | -1.4% |
| EPS needed in final year | $0.22 | $0.22 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PLX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.